Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Decheng Capital Files for $700 Million Global Life Sciences Fund

publication date: Jun 18, 2024

Decheng Capital announced plans for a $700 million global life sciences fund, its fifth life sciences vehicle. The company, which has offices in Silicon Valley, Shanghai and New York, has $2.1 billion in assets under management. Since its founding in 2012, Decheng has invested in novel drug companies and medical device makers, along with diagnostics and tools companies. Previously, Dechang’s fourth fund raised $650 million in 2021, and the third fund aimed to close at $450 million in 2018. Decheng has offices in Shanghai, New York and Silicon Valley. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here